CELLECTAR BIOSCIENCES, INC.
CLR 131, a radio-iodinated therapeutic molecule comprising a phospholipid ether analogue labeled with iodine-131 for targeted cancer treatment
- Sector
- Biotech
- Headquarters
- FLORHAM PARK, NJ
- Latest Form D
- $24.5M, Sep 2023
- Total capital
- $103M
- Federal grants
- $4M
- 5 awards · 2021–2023
- Rank in peer group#238 of 514
- Private capital raised
- $99.3M
- 8 Form D · last Sep 2023
- 37 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 14 pending · first 2016
- Rank in peer group#48 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$24.5M
- Federal grantHealth and Human S · Phase II · An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$476K
- Federal grantHealth and Human S · Phase II · A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma$965K
- Federal grantHealth and Human S · Phase II · A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma$1M
- Federal grantHealth and Human S · Phase II · An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$756K
- Federal grantHealth and Human S · Phase II · An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$763K
- Private capital raisedForm D · SEC · 7th filing$20.5M
- Private capital raisedForm D · SEC · 6th filing$5M
- Private capital raisedForm D · SEC · 5th filing$7.8M
- Private capital raisedForm D · SEC · 4th filing$618K
- Private capital raisedForm D · SEC · 3rd filing$5.1M
- Private capital raisedForm D · SEC · 2nd filing$3.5M
- Private capital raisedForm D · SEC · 1st filing$32.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#238 · top 46%
- Granted patents#48 · top 9%
- Linked publications#84 · top 16%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jamey P. WeichertResearcherExecutive Officer, DirectorLinked by 5 patents
- Jarrod J. LongcorResearcherExecutive OfficerLinked by 2 patents · $2M in grants as PI
- Andrei Shane ShustovExecutive OfficerNamed in SEC Form D filings
- Asher Alban Chanan-KahnDirectorNamed in SEC Form D filings
- Chad J. KoleanExecutive OfficerNamed in SEC Form D filings
- Charles T. BernhardtExecutive OfficerNamed in SEC Form D filings
Show all 19 people
- Darrell Shane LeaExecutive OfficerNamed in SEC Form D filings
- Douglas J. SwirskyDirectorNamed in SEC Form D filings
- Dov ElefantExecutive OfficerNamed in SEC Form D filings
- Frederick W DriscollDirectorNamed in SEC Form D filings
- James V. CarusoExecutive Officer, DirectorNamed in SEC Form D filings
- John J. FriendDirectorNamed in SEC Form D filings
- John E. Friend IIExecutive OfficerNamed in SEC Form D filings
- John P. HamillExecutive OfficerNamed in SEC Form D filings
- John P. NeisDirectorNamed in SEC Form D filings
- Paul P. BernsDirectorNamed in SEC Form D filings
- Simon PedderExecutive Officer, DirectorNamed in SEC Form D filings
- Stefan D. LorenDirectorNamed in SEC Form D filings
- Stephen A. HillDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 21- GrantedPhospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer TherapyUSPTOUS 12,503,479
- GrantedPhospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer TherapyUSPTOUS 12,496,346
- PendingFractionated Dosing of a Phospholipid Ether Analog for the Treatment of CancerUSPTOApplication 17768420
Show all 21 patent records
- Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer TherapyDec 23, 2025 · US 12,503,479Granted
- Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer TherapyDec 16, 2025 · US 12,496,346Granted
- Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of CancerApr 25, 2024 · Application 17768420Pending
- Phospholipid Ether Conjugates as Cancer-Targeting Drug VehiclesMar 2, 2023 · Application 17642561Pending
- Luminescent Phospholipid Analogs For The Identification And Isolation Of Circulating Tumor CellsOct 11, 2022 · US 11,467,159Granted
- Phospholipid Ether Analogs as Cancer-Targeting Drug VehiclesSep 13, 2022 · US 11,439,709Granted
- Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of CancerApr 15, 2021 · Application 17044752Pending
- Phospholipid Ether Analogs as Cancer-Targeting Drug VehiclesMar 27, 2018 · US 9,925,269Granted
- Phospholipid Ether Analogs as Cancer-Targeting Drug VehiclesNov 1, 2016 · US 9,480,754Granted
- Phospholipid Ether Analogs as Cancer-Targeting Drug VehiclesMay 24, 2016 · US 9,345,718Granted
- Phospholipid-flavagline Conjugates And Methods Of Using The Same For Targeted Cancer TherapyApplication PCTUS2019026853Pending
- Fractionated Dosing Of A Phospholipid Ether Analog For The Treatment Of CancerApplication PCTUS2019026828Pending
- Efficacy of Fractionated Injections of CLR 131 in an OPM-2 Mouse ModelApplication 62655615Pending
- Phospholipid Drug Conjugates (PDC?) Show Specificity for a Broad Range of Tumor Cells and Provides a Novel Approach for Targeted or Precision TherapyApplication 62655659Pending
- Phospholipid Ether Conjugates As Cancer-targeting Drug VehiclesApplication PCTUS2020050459Pending
- Phospholipid-flavagline Conjugates And Methods Of Using The Same For Targeted Cancer TherapyApplication PCTUS2020055121Pending
- Phospholipid Ether Analogs For The Identification And Isolation Of Circulating Tumor CellsApplication PCTUS2017037549Pending
- Phospholipid Ether Analogs As Cancer-targeting Drug VehiclesApplication PCTUS2015059382Pending
- Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of CancerApplication 62913522Pending
- Fractionated Dosing Of A Phospholipid Ether Analog For The Treatment Of CancerApplication PCTUS2020055037Pending
- Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer TherapyApplication 62913571Pending
Recent research by its founders
- A Phase I Trial of Iopofosine I 131 and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma20260 cites
- Iopofosine I-131 after BTK inhibitors in Waldenström macroglobulinemia: CLOVER-WaM subgroup efficacy and safety.20260 cites
- Abstract A019: Precision radiotherapy for incurable brain tumors: Phase 1b dose & regimen optimization study of iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade glioma, interim data assessment20250 cites
Related companies, and why
- SepternaSimilar federal contract value in Biotech · null in contracts
- APERTURE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- ABEOME CORPORATIONSimilar federal contract value in Biotech · null in contracts
- PAVAJ VASCULAR CORPORATIONSimilar federal contract value in Biotech · null in contracts
- CELLERGY PHARMASimilar federal contract value in Biotech · null in contracts
- DIRECTSEQ BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .